Qi Wang1, Robert H Mach, Robert R Luedtke, David E Reichert. 1. Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St. Louis, Missouri 63110, USA.
Abstract
Subtype selective dopamine receptor ligands have long been sought after as therapeutic and/or imaging agents for the treatment and monitoring of neurologic disorders. We report herein on a combined structure- and ligand-based approach to explore the molecular mechanism of the subtype selectivity for a large class of D₂-like dopamine receptor ligands (163 ligands in total). Homology models were built for both human D(₂L) and D₃ receptors in complex with haloperidol. Other ligands, which included multiple examples of substituted phenylpiperazines, were aligned against the binding conformations of haloperidol, and three-dimensional quantitative structure activity relationship (3D-QSAR) analyses were carried out. The receptor models show that although D₂ and D₃ share highly similar folds and 3D conformations, the slight sequence differences at their extracellular loop regions result in the binding cavity in D₂ being comparably shallower than in D₃, which may explain why some larger ligands bind with greater affinity at D₃ compared to D₂ receptors. The QSAR models show excellent correlation and high predictive power even when evaluated by the most stringent criteria. They confirm that the origins of subtype selectivity for the ligands arise primarily due to differences in the contours of the two binding sites. The predictive models suggest that while both steric and electrostatic interactions contribute to the compounds' binding affinity, the major contribution arises from hydrophobic interactions, with hydrogen bonding conferring binding specificity. The current work provides clues for the development of more subtype selective dopamine receptor ligands. Furthermore, it demonstrates the possibility of being able to apply similar modeling methods to other subtypes or classes of receptors to study GPCR receptor-ligand interactions at a molecular level.
Subtype selective dopamine receptor ligands have long been sought after as therapeutic and/or imaging agents for the treatment and monitoring of n class="Disease">neurologic disorders. We report herein on a combined structure- and ligand-based approach to explore the molecular mechanism of the subtype selectivity for a large class of D₂-like dopamine receptor ligands (163 ligands in total). Homology models were built for both human D(₂L) and D₃ receptors in complex with haloperidol. Other ligands, which included multiple examples of substituted phenylpiperazines, were aligned against the binding conformations of haloperidol, and three-dimensional quantitative structure activity relationship (3D-QSAR) analyses were carried out. The receptor models show that although D₂ and D₃ share highly similar folds and 3D conformations, the slight sequence differences at their extracellular loop regions result in the binding cavity in D₂ being comparably shallower than in D₃, which may explain why some larger ligands bind with greater affinity at D₃ compared to D₂ receptors. The QSAR models show excellent correlation and high predictive power even when evaluated by the most stringent criteria. They confirm that the origins of subtype selectivity for the ligands arise primarily due to differences in the contours of the two binding sites. The predictive models suggest that while both steric and electrostatic interactions contribute to the compounds' binding affinity, the major contribution arises from hydrophobic interactions, with hydrogen bonding conferring binding specificity. The current work provides clues for the development of more subtype selective dopamine receptor ligands. Furthermore, it demonstrates the possibility of being able to apply similar modeling methods to other subtypes or classes of receptors to study GPCR receptor-ligand interactions at a molecular level.
Authors: Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke Journal: J Med Chem Date: 2009-04-23 Impact factor: 7.446
Authors: Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang Journal: Curr Pharm Des Date: 2012 Impact factor: 3.116
Authors: Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach Journal: ACS Chem Neurosci Date: 2012-10-12 Impact factor: 4.418
Authors: Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke Journal: J Neurochem Date: 2014-08-19 Impact factor: 5.372
Authors: Sean W Reilly; Suzy Griffin; Michelle Taylor; Kristoffer Sahlholm; Chi-Chang Weng; Kuiying Xu; Daniel A Jacome; Robert R Luedtke; Robert H Mach Journal: J Med Chem Date: 2017-11-21 Impact factor: 7.446
Authors: Aixiao Li; Yogesh Mishra; Maninder Malik; Qi Wang; Shihong Li; Michelle Taylor; David E Reichert; Robert R Luedtke; Robert H Mach Journal: Bioorg Med Chem Date: 2013-04-06 Impact factor: 3.641
Authors: T H C Cheung; B C Nolan; L R Hammerslag; S M Weber; J P Durbin; N A Peartree; R H Mach; R R Luedtke; J L Neisewander Journal: Neuropharmacology Date: 2012-08-31 Impact factor: 5.250